Kura Oncology Inc reports results for the quarter ended December 31 - Earnings Summary
26/02/2025 22:01
Kura Oncology Inc KURA.OQ reported a quarterly adjusted loss of 22 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -55 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 64 cents per share. Wall Street expected results to range from -75 cents to -39 cents per share. Revenue was $53.88 million; analysts expected $8.50 million. Kura Oncology Inc's reported EPS for the quarter was a loss of 22 cents. The company reported a quarterly loss of $19.22 million. Kura Oncology Inc shares had fallen by 9.5% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 0.3% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Kura Oncology Inc is $28.00 This summary was machine generated from LSEG data February 26 at 10:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.64 | -0.22 | Beat |
| Sep. 30 2024 | -0.63 | -0.63 | Met |
| Jun. 30 2024 | -0.63 | -0.59 | Beat |
| Mar. 31 2024 | -0.55 | -0.59 | Missed |